Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 6/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | DHPS | P49366 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169067 | 0.84 | KCNA5 (0.50) | SQORADORA1KCNA5KCNH2 | |
| SCHEMBL2168453 | 0.74 | KCNA5 (0.58) | SQORADORA1KCNA5KCNH2 | |
| SCHEMBL5519238 | 0.73 | SQOR (0.39) | SQOR | |
| SCHEMBL1382542 | 0.70 | KCNA5 (0.67) | SQORADORA1KCNA5KCNH2DHPS | |
| SCHEMBL6047739 | 0.70 | KCNA5 (0.67) | SQORADORA1KCNA5KCNH2DHPS | |
| SCHEMBL3111674 | 0.70 | KCNA5 (0.67) | SQORADORA1KCNA5KCNH2DHPS | |
| SCHEMBL2167818 | 0.68 | KCNA5 (0.43) | SQORADORA1KCNA5KCNH2 | |
| SCHEMBL3625695 | 0.67 | KCNA5 (0.62) | KCNA5KCNH2 | |
| SCHEMBL4342810 | 0.66 | KCNA5 (0.52) | SQORADORA1KCNA5KCNH2 | |
| SCHEMBL4342811 | 0.66 | KCNA5 (0.52) | SQORADORA1KCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | KCNH2, KCNJ2, KCNQ1 | SQOR 259/4885ADORA1 1041/4885KCNA5 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.